No Data
BOCOM INTL investment ratings and Target Price for pharmaceutical stocks (table)
BOCOM INTL released a research report, listing the investment ratings and Target Prices for pharmaceutical stocks as follows: Stock | Investment Rating | Target Price AstraZeneca (AZN.US) | Buy | $93.3 BEIGENE (06160.HK) | Buy | HK$208.8 HANSOH PHARMA (03692.HK) | Buy | HK$33 INNOVENT BIO (01801.HK) | Buy | HK$84 SINO BIOPHARM (01177.HK) | Buy | HK$5.9 Corum Bio-Technology - B (06990.HK) |
China Securities Co.,Ltd.: Bullish on new opportunities and industry consolidation in the Pharmaceutical Industry for the second half of the year.
Looking ahead to the second half of 2025, there is continued optimism for new growth (innovation, going overseas, marginal changes) and opportunities for Industry consolidation.
HUTCHMED (China) Limited Outlines Audit Committee Responsibilities
HUTCHMED (China) Limited Strengthens Governance With New Nomination Committee Terms
Recent market hotspots continue to rotate between high and low, focusing on varieties with certainty in mid-term report performance.
Track the entire lifecycle of the main Sector.
[Popular Industry] The valuation logic of innovative drugs in China is accelerating reconstruction. Will the Industry enter a 2-3 year upward period?
Jinwu Financial News | Since the beginning of this year, the medical Sector, especially in the field of Yinhua CSI Innovative Drugs Industry ETF, has seen unprecedented enthusiasm. The cumulative increases of the Hong Kong Stock Connect Yinhua CSI Innovative Drugs Industry ETF (159570), Hwabao WP CSI Medical Service ETF (159506), and Hang Seng Biotechnology ETF (159615) year-to-date are 52%, 48.7%, and 44.9% respectively. Among them, the net Inflow of the Hong Kong Stock Connect Yinhua CSI Innovative Drugs Industry ETF in June has reached 1.916 billion yuan, expected to surpass the combined total of net Inflow in April and May. The strong performance of the Sector is supported by multiple catalytic factors, including policy support and valuation reconstruction, as well as new trends such as international BD cooperation and AI in pharmaceuticals.
